Inaedis

The company describes a platform for multiple drug delivery routes and formulation strategies, including monoclonal antibodies above 500 mg/mL and subcutaneous injections. It says these can reduce administration time by hours and enable at-home self-administration.

The page reports that Prof. John Carpenter reviewed Inaedis’s study on rapid room-temperature aerosol dehydration versus spray drying, published in the Journal of Pharmaceutical Sciences.

Inaedis, Inc. closed a pre-seed investment from Roadrunner Venture Studios to continue developing its platform biotechnology company.

Princeton University researchers developed Rapid Room-Temperature Dehydration Technology, which was selected by the University City Science Center for further funding and development.

A joint study by Inaedis, Inc. and researchers from a pharmaceutical company found that Inaedis’s rapid room-temperature aerosol dehydration methods offered improved outcomes compared with traditional drying techniques.

Inaedis, Inc. received $150,000 in non-dilutive funding from the Catalyst Seed R&D Grant Program, a state-led initiative supporting deep biotechnology ventures in New Jersey.

INAEDIS’s team includes researchers with scientific expertise from Princeton University and members of the National Academies, as well as startup and pharmaceutical industry veterans.

Transforming Biologic Formulation and Administration to Deliver Health

Inaedis develops a scalable, cGMP-compatible platform to address formulation, manufacturing, and delivery constraints for biologics, which can be expensive, fragile, cold-chain dependent, and tied to invasive administration.

Inaedis’s scalable, cGMP-compatible RTAD technology converts liquid biologics into room-temperature-stable formulations and enables patient-centric drug administration and shelf stability.

Inaedis received a $209,565 Department of Defense SBIR Phase I contract to develop thermostable biologic formulations and vaccines.

Sep 2025 · InaedisNews article

Inaedis was selected for the Merck Digital Sciences Studio cohort. The company will develop its biologic formulation technology through the cohort.

Nov 2024 · InaedisNews article